P1.12-07 Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer

Genetic alterations in the KEAP1-NFE2L2 pathway, leading to abnormal activation of nuclear factor erythroid 2-related factor 2 (NRF2), are frequently observed in non-small cell lung cancer (NSCLC). These alterations are associated with aggressive phenotypes and resistance to therapy. Despite this, directly targeting NSCLC with hyperactivated NRF2 remains clinically challenging. Recent studies propose that targeting ferroptosis, a regulated form of non-apoptotic cell death, could be a promising strategy for overcoming drug resistance in cancer treatment.